Lincoln International’s Global Healthcare Group Announces Strong Results in 2022

Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance is especially notable given global healthcare M&A volumes saw a modest pull back in 2022 brought on by instability in the labor market, higher inflation and interest rates, pressure on reimbursements and the waning influence of COVID-19-era government-funded supports.

Despite these macro influences, we expect 2023 to be another active year for healthcare dealmaking as industry players and private equity utilize M&A as a strategy to keep pace with the ever-increasing complexities across healthcare access, quality and cost; regulatory pressures; reimbursement rates; software and technology integration; payment reforms and advances in pharma and medical technology.

Our team has deep domain expertise and transaction experience across a number of high growth areas of the global healthcare economy including:

  • Animal health
  • Behavioral and mental health
  • Fertility and women’s health
  • Healthcare IT and tech-enabled services
  • Home and community based care
  • Labs and lab services
  • Payor services and employer-funded insurance services
  • Pharma and medtech outsourcing
  • Physical / occupational / speech therapy and rehab
  • Physician services and ambulatory care
  • Value-based care enablement
  • Revenue cycle management


  • Lincoln International's Global Healthcare Group announces strong results in 2022.

Select Notable 2022 Healthcare Transactions

Related Perspectives

Real Deals | Healthcare M&A Resilience

What trends have you seen in the last quarter in relation to valuations in the healthcare space? Matthew Lee: It’s early days to get an accurate read on valuations as… Read More

Lincoln International Announces Strategic Partnership with Australian Corporate Advisory Firm, Miles Advisory Partners

Lincoln International, a global investment banking advisory firm, announced today that it has established a strategic partnership with Miles Advisory Partners, an Australian-based independent corporate advisory firm, servicing the robust… Read More

Scrip | What Does 2023 Hold for Biopharma? Part 6: Artificial Intelligence

Originally posted by Scrip on February 10, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for artificial intelligence in the biopharma industry. View the original article.

2022 Global Results

In 2022, Lincoln International continued to design and deliver meaningful solutions and outcomes for clients around the world. Our shared ambition for results achieved through collaboration, thoughtfulness and tailored approaches… Read More

Meet Our Senior Team in Healthcare